Table 2.
Survival analyses for prognosticators of progression-free survival in epithelioid glioblastoma patients
| Parameter | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% Confidence Interval | P | HR | 95% Confidence Interval | P | |
| Age | 1.007 | 0.985–1.029 | 0.524 | |||
| Sex | 1.247 | 0.659–2.362 | 0.498 | |||
| Tumor stroke | 0.886 | 0.387–2.027 | 0.774 | |||
| Tumor dissemination | 1.974 | 1.039–3.750 | 0.038 | 2.652 | 1.189–5.916 | 0.017 |
| Extent of resection | ||||||
| GTR | 1 (Reference) | 1 (Reference) | ||||
| STR | 1.873 | 0.708–4.957 | 0.206 | 0.653 | 0.202–2.110 | 0.477 |
| PR | 2.848 | 1.186–6.837 | 0.019 | 1.600 | 0.606–4.226 | 0.343 |
| Pre-operative KPS | 1.010 | 0.989–1.031 | 0.354 | |||
| Concomitant chemoradiotherapy | 0.572 | 0.284–1.154 | 0.119 | 0.676 | 0.302–1.515 | 0.341 |
| Adjuvant oral TMZ | 0.404 | 0.204–0.799 | 0.009 | 0.354 | 0.160–0.786 | 0.011 |
| Ki-67 | 0.612 | 0.277–1.354 | 0.225 | |||
| BRAF-V600E | 1.691 | 0.870–3.287 | 0.121 | 0.772 | 0.364–1.637 | 0.500 |
| MGMT | 0.920 | 0.484–1.748 | 0.799 | |||
| GFAP | 1.020 | 0.358–2.907 | 0.970 | |||
| ATRX | 1.257 | 0.481–3.281 | 0.641 | |||
| Olig-2 | 0.618 | 0.188–2.035 | 0.429 | |||
| P53 | 0.897 | 0.460–1.750 | 0.750 | |||
GTR Gross Total Resection, STR Subtotal Resection, PR Partial Resection, KPS Karnofsky Performance Scale, TMZ temozolomide, MGMT Methylguanine DNA Methyltransferase, GFAP Glial Fibrillary Acidic Protein, ATRX X-linked alpha-thalassemia mental retardation syndrome, Olig-2 Oligodendrocyte Transcription Factor 2